Practical considerations for developing nucleoside reverse transcriptase inhibitors

Drug Discovery Today: Technologies

Volumn 9, Issue 3, 2012, Pages

  Hurwitz, Selwyn J ^a,b   Schinazi, Raymond F ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4' ETHYNYL 2 FLUORO 2' DEOXYADENOSINE; ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMDOXOVIR; DIDANOSINE; DIOXOLANE GUANOSINE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; EMTRICITABINE PLUS RILPIVIRINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FESTINAVIR; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; MARAVIROC; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PAMIDRONIC ACID; PLACEBO; PRODRUG; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; TENOFOVIR 3 HEXADECYLOXYPROPYL ESTER; TENOFOVIR ALAFENAMIDE; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; VIR S 30; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; BONE MARROW TOXICITY; CD4 LYMPHOCYTE COUNT; COMPETITIVE INHIBITION; COMPUTER MODEL; CREATININE CLEARANCE; CROSS RESISTANCE; DOSE CALCULATION; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG STABILITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TRANSPORT; DRUG WITHDRAWAL; ENZYME PHOSPHORYLATION; GENOTOXICITY; GLUCOSURIA; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; IN VIVO STUDY; INSOMNIA; INTESTINE LYMPHATIC TISSUE; LACTIC ACIDOSIS; LIPODYSTROPHY; MACROPHAGE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MYOPATHY; NIGHTMARE; NONHUMAN; PANCREATITIS; PATIENT COMPLIANCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL NEUROPATHY; PHOSPHATURIA; PROTEINURIA; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION; VIRUS LOAD; VIRUS RESISTANCE;

EID: 84873095350     PISSN: None     EISSN: 17406749     Source Type: Journal    
DOI: 10.1016/j.ddtec.2012.09.003     Document Type: Review

References (103)

1. Broder, S. (2010) The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res. 85, 1-18
2. Cihlar, T. and Ray, A.S. (2010) Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. Antiviral Res. 85, 39-58
3. Este, J.A. and Cihlar, T. (2010) Current status and challenges of antiretroviral research and therapy. Antiviral Res. 85, 25-33
4. Siliciano, J.D. and Siliciano, R.F. (2006) The latent reservoir for HIV-1 in resting CD4+ T cells: a barrier to cure. Curr. Opin. HIV AIDS 1, 121-128
5. Pereira, C.F. and Paridaen, J.T. (2004) Anti-HIV drug development - an overview. Curr. Pharm. Des. 10, 4005-4037
6. Schinazi, R.F. et al. (2006) Pharmacology of current and promising nucleosides for the treatment of human immunodeficiency viruses. Antiviral Res. 71, 322-334
7. Hediger, M.A. et al. (2004) The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins. Introduction. Pflugers Arch. 447, 465-468
8. Plagemann, P.G. et al. (1988) Nucleoside and nucleobase transport in animal cells. Biochim. Biophys. Acta 947, 405-443
9. Schuetz, J.D. et al. (1999) MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat. Med. 5, 1048-1051
10. Bethell, R. et al. (2007) In vitro interactions between apricitabine and other deoxycytidine analogues. Antimicrob. Agents Chemother. 51, 2948-2953
11. Havlir, D.V. et al. (2000) In vivo antagonism with zidovudine plus stavudine combination therapy. J. Infect. Dis. 182, 321-325
12. Ray, A.S. and Hitchcock, M.J.M. (2009) Metabolism of antiviral nucleosides and nucleotides. In Antiviral Research: Strategies in Antiviral Drug Discovery (Lafemina, R.L., ed.), ASM Press
13. Jacobsson, B. et al. (1998) Decrease in thymidylate kinase activity in peripheral blood mononuclear cells from HIV-infected individuals. Biochem. Pharmacol. 56, 389-395
14. Nitanda, T. et al. (2005) Anti-human immunodeficiency virus type 1 activity and resistance profile of 2,3′-didehydro-3′-deoxy-4′- ethynylthymidine in vitro. Antimicrob. Agents Chemother. 49, 3355-3360
15. Paintsil, E. et al. (2007) Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2′,3′-didehydro- 3′-deoxy-4′-ethynylthymidine, a novel thymidine analog. Antimicrob. Agents Chemother. 51, 3870-3879
16. Barry, M.G. et al. (1996) The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites. AIDS 10, 1361-1367
17. Becher, F. et al. (2004) Monitoring of didanosine and stavudine intracellular trisphosphorylated anabolite concentrations in HIVinfected patients. AIDS 18, 181-187
18. Hurwitz, S.J. et al. (2008) Development of an optimized dose for coformulation of zidovudine with drugs that select for the K65R mutation using a population pharmacokinetic and enzyme kinetic simulation model. Antimicrob. Agents Chemother. 52, 4241-4250
19. Hurwitz, S.J. and Schinazi, R.F. (2011) In silico study supports the efficacy of a reduced dose regimen for stavudine. Antiviral Res. 92, 372-377
20. Jacobsson, B. et al. (1995) Decreased thymidine kinase levels in peripheral blood cells from HIV-seropositive individuals: implications for zidovudine metabolism. AIDS Res. Hum. Retroviruses 11, 805-811
21. Hellerstein, M. et al. (1999) Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nat. Med. 5, 83-89
22. Mohri, H. et al. (2001) Increased turnover of T lymphocytes in HIV-1 infection and its reduction by antiretroviral therapy. J. Exp. Med. 194, 1277-1287
23. Fletcher, C.V. (1999) Pharmacologic considerations for therapeutic success with antiretroviral agents. Ann. Pharmacother. 33, 989-995
24. Kohler, J.J. and Lewis, W. (2007) A brief overview of mechanisms of mitochondrial toxicity from NRTIs. Environ. Mol. Mutagen. 48, 166-172
25. Carr, A. et al. (2000) A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 14, F25-F32
26. Feng, J.Y. et al. (2004) Relationship between antiviral activity and host toxicity: comparison of the incorporation efficiencies of 20,30-dideoxy-5- fluoro-30-thiacytidine-triphosphate analogs by human immunodeficiency virus type 1 reverse transcriptase and human mitochondrial DNA polymerase. Antimicrob. Agents Chemother. 48, 1300-1306
27. Johnson, A.A. et al. (2001) Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J. Biol. Chem. 276, 40847-40857
28. Stuyver, L.J. et al. (2002) Antiviral activities and cellular toxicities of modified 2′,3′-dideoxy-2′,3′-didehydrocytidine analogues. Antimicrob. Agents Chemother. 46, 3854-3860
29. Bassit, L. et al. (2008) Comparison of two human pancreatic cell lines for predicting mitochondrial toxicity by nucleoside analogs. HIV DART 2008 Global Antiviral J. 4 (Suppl. 1), 56 Abstract 50
30. Gallant, J.E. et al. (2008) The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviralnaive patients. AIDS 22, 2155-2163
31. Cihlar, T. et al. (2001) Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids 20, 641-648
32. Kohler, J.J. et al. (2009) Tenofovir renal toxicity targets mitochondria of renal proximal tubules. Lab. Invest. 89, 513-519
33. Kristoffersen, U.S. et al. (2009) Changes in biomarkers of cardiovascular risk after a switch to abacavir in HIV-1-infected individuals receiving combination antiretroviral therapy. HIV Med. 10, 627-633
34. Sabin, C.A. et al. (2008) Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 371, 1417-1426
35. Kohler, J.J. et al. (2010) Absence of mitochondrial toxicity in hearts of transgenic mice treated with abacavir. Cardiovasc. Toxicol. 10, 146-151
36. Lundgren, J.D. et al. (2008) Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 22, F17-F24
37. Martin, A.M. et al. (2004) Predisposition to abacavir hypersensitivity conferred by HLA-B&z.ast;5701 and a haplotypic Hsp70-Hom variant. Proc. Natl. Acad. Sci. U.S.A. 101, 4180-4185
38. Ward, J.L. and Tse, C.M. (1998) Identification of the nucleoside transporters in human small intestine and colonic epithelial cell lines. Gastroenterology 114, A431
39. Hurwitz, S.J. et al. (2005) Comparative pharmacokinetics of Racivir, (+/-)- beta-2′,3′-dideoxy-5-fluoro-3′-thiacytidine in rats, rabbits, dogs, monkeys and HIV-infected humans. Antivir. Chem. Chemother. 16, 117-127
40. Hall, A.M. et al. (2011) Tenofovir-associated kidney toxicity in HIVinfected patients: a review of the evidence. Am. J. Kidney Dis. 57, 773-780
41. Tippin, T.K. et al. (2010) Lipid conjugates of cidofovir and tenofovir are not substrates of human organic ion transporters hOAT1 and hOAT3. World Congress and American Association of Pharmaceutical Scientists Abstract # T3396
42. Neely, M.N. and Rakhmanina, N.Y. (2011) Pharmacokinetic optimization of antiretroviral therapy in children and adolescents. Clin. Pharmacokinet. 50, 143-189
43. Anderson, B.J. et al. (2006) Population clinical pharmacology of children: general principles. Eur. J. Pediatr. 165, 741-746
44. Jullien, V. et al. (2005) Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy. Antimicrob. Agents Chemother. 49, 3361-3366
45. Zhao, W. et al. (2012) Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: application of individualized therapy in HIV-infected infants and toddlers. Br. J. Clin. Pharmacol. 73, 641-650
46. Sales, S.D. et al. (2001) Zidovudine phosphorylation and mitochondrial toxicity in vitro. Toxicol. Appl. Pharmacol. 177, 54-58
47. Murphy, R.L. et al. (2010) Antiviral activity and tolerability of amdoxovir with zidovudine in a randomized double-blind placebo-controlled study in HIV-1-infected individuals. Antivir. Ther. 15, 185-192
48. Casiro, A.D. (2011) The evolving role of stavudine as part of initial antiretroviral therapy in resource-constrained settings.
49. Sinxadi, P.Z. et al. (2010) Lack of association between stavudine exposure and lipoatrophy, dysglycaemia, hyperlactataemia and hypertriglyceridaemia: a prospective cross sectional study. AIDS Res. Ther. 7, 23
50. Perelson, A.S. (2002) Modelling viral and immune system dynamics. Nat. Rev. Immunol. 2, 28-36
51. Markowitz, M. et al. (2003) A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J. Virol. 77, 5037-5038
52. Rosario, M.C. et al. (2006) A pharmacokinetic-pharmacodynamic model to optimize the phase IIa development program of maraviroc. J. Acquir. Immune Defic. Syndr. 42, 183-191
53. Bonhoeffer, S. et al. (1997) Virus dynamics and drug therapy. Proc. Natl. Acad. Sci. U.S.A. 94, 6971-6976
54. Hurwitz, S.J. et al. (2007) Development of a population simulation model for HIV monotherapy virological outcomes using lamivudine. Antivir. Chem. Chemother. 18, 329-341
55. Chun, T.W. and Fauci, A.S. (2012) HIV reservoirs: pathogenesis and obstacles to viral eradication and cure. AIDS 26, 1261-1268
56. Smith, M.Z. et al. (2012) HIV reservoirs and strategies for eradication. Curr. HIV/AIDS Rep. 9, 5-15
57. Gavegnano, C. and Schinazi, R.F. (2009) Antiretroviral therapy in macrophages: implication for HIV eradication. Antivir. Chem. Chemother. 20, 63-78
58. Else, L.J. et al. (2011) Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. Antivir. Ther. 16, 1149-1167
59. Heneine, W. and Kashuba, A. (2012) HIV prevention by oral preexposure prophylaxis. Cold Spring Harb. Perspect. Med. 2, a007419
60. Patterson, K. et al. (2010) Exposure of extracellular and intracellular tenofovir and emtricitabine in mucosal tissues after a single of fixed-dose TDF/FTC: implications for pre-exposure HIV prophylaxis (PrEP). XVIII International AIDS Conference
61. van Marle, G. et al. (2010) Higher levels of zidovudine resistant HIV in the colon compared to blood and other gastrointestinal compartments in HIV infection. Retrovirology 7, 74
62. Ananworanich, J. et al. (2012) Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS One 7, e33948
63. Sips, M. et al. (2012) Altered distribution of mucosal NK cells during HIV infection. Mucosal Immunol. 5, 30-40
64. Heaton, R.K. et al. (2010) HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 75, 2087-2096
65. Letendre, S. et al. (2008) Validation of the CNS Penetration- Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch. Neurol. 65, 65-70
66. Marra, C.M. et al. (2009) Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 23, 1359-1366
67. Shikuma, C.N.B. et al. Antiretroviral monocyte efficacy score linked to cognitive impairment in HIV. Antivir Ther (in press)
68. Fischer-Smith, T. et al. (2008) Monocyte/macrophage trafficking in acquired immunodeficiency syndrome encephalitis: lessons from human and nonhuman primate studies. J. Neurovirol. 14, 318-326
69. Gras, G. and Kaul, M. (2010) Molecular mechanisms of neuroinvasion by monocytes-macrophages in HIV-1 infection. Retrovirology 7, 30
70. Kennedy, E.M. et al. (2010) Ribonucleoside triphosphates as substrate of human immunodeficiency virus type 1 reverse transcriptase in human macrophages. J. Biol. Chem. 285, 39380-39391
71. Ruane, P.J. and Luber, A.D. (2004) K65R-associated virologic failure in HIV-infected patients receiving tenofovir-containing triple nucleoside/ nucleotide reverse transcriptase inhibitor regimens. MedGenMed 6, 31
72. Winston, A. et al. (2002) The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients. AIDS 16, 2087-2089
73. Schinazi, R.F. et al. (1993) Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob. Agents Chemother. 37, 875-881
74. McColl, D.J. et al. (2011) Reduced emergence of the M184V/I resistance mutation when antiretroviral-naive subjects use emtricitabine versus lamivudine in regimens composed of two NRTIs plus the NNRTI efavirenz. HIV Clin. Trials 12, 61-70
75. Schinazi, R.F. et al. (2011) Selection and characterization of HIV-1 with a novel S68 deletion in reverse transcriptase. Antimicrob. Agents Chemother. 55, 2054-2060
76. Turner, D. et al. (2003) Multiple effects of the M184V resistance mutation in the reverse transcriptase of human immunodeficiency virus type 1. Clin. Diagn. Lab. Immunol. 10, 979-981
77. Scourfield, A. et al. (2012) Discontinuation of Atripla as first-line therapy in HIV-1 infected individuals. AIDS 26, 1399-1401
78. McComsey, G. and Lonergan, J.T. (2004) Mitochondrial dysfunction: patient monitoring and toxicity management. J. Acquir. Immune Defic. Syndr. 37 (Suppl. 1), S30-S35
79. Hurwitz, S.J. et al. (2010) Lack of pharmacokinetic interaction between amdoxovir and reduced- and standard-dose zidovudine in HIV-1-infected individuals. Antimicrob. Agents Chemother. 54, 1248-1255
80. Feng, J.Y. et al. (2004) Anabolism of amdoxovir: phosphorylation of dioxolane guanosine and its 50-phosphates by mammalian phosphotransferases. Biochem. Pharmacol. 68, 1879-1888
81. Seigneres, B. et al. (2002) Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses. Hepatology 36, 710-722
82. Mewshaw, J.P. et al. (2002) Dioxolane guanosine, the active form of the prodrug diaminopurine dioxolane, is a potent inhibitor of drug-resistant HIV-1 isolates from patients for whom standard nucleoside therapy fails. J. Acquir. Immune Defic. Syndr. 29, 11-20
83. Kewn, S. et al. (2003) Enzymatic assay for measurement of intracellular DXG triphosphate concentrations in peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected patients. Antimicrob. Agents Chemother. 47, 255-261
84. Cui, L. et al. (1996) Effect of beta-enantiomeric and racemic nucleoside analogues on mitochondrial functions in HepG2 cells. Implications for predicting drug hepatotoxicity. Biochem. Pharmacol. 52, 1577-1584
85. Parikh, U.M. et al. (2005) In vitro activity of structurally diverse nucleoside analogs against human immunodeficiency virus type 1 with the K65R mutation in reverse transcriptase. Antimicrob. Agents Chemother. 49, 1139-1144
86. Rapp, K.L. et al. (2007) The combination of zidovudine and amdoxovir prevents the selection of thymidine analog mutations in primary human lymphocytes. XVI International HIV Drug Resistance Workshop pp. S130
87. Trost, L.C. et al. (2010) Preclinical evaluation of CMX157: a lipidconjugated nucleotide analog for the treatment of HIV. 49th SOT Meeting Abstract # 1057-216
88. Lanier, E.R. et al. (2010) Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/ nucleotide-resistant HIV. Antimicrob. Agents Chemother. 54, 2901-2909
89. Painter, G.R. et al. (2007) Evaluation of hexadecyloxypropyl-9-R-[2- (phosphonomethoxy)propyl]-adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections. Antimicrob. Agents Chemother. 51, 3505-3509
90. Lanier, R. et al. (2009) Hexadecyloxypropyl tenofovir associates directly with HIV and subsequently inhibits viral replication in untreated cells. 16th Conference on retroviruses and Opportunistic Infections, Montreal, Canada Abstract 556
91. Markowitz, M. et al. (2011) GS-7340 demonstrates greater declines in HIV-1 RNA than tenofovir disoproxil fumarate during 14 days of monotherapy in HIV-1 infected subjects. 18th Conference on Retroviruses and Opportunistic Infections Abstract # 568
92. Ruane, P. et al. (2012) GS-7340 25 mg and 40 mg demonstrate superior efficacy to tenofovir 300 mg in a 10-day monotherapy study of HIV-1+ patients. 18th Conference on Retroviruses and Opportunistic Infections Abstract # 103, # 568
93. Lee, W.A. et al. (2005) Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob. Agents Chemother. 49, 1898-1906
94. Birkus, G. et al. (2008) Activation of 9-[(R)-2-[[(S)-[[(S)-1- (Isopropoxycarbonyl)ethyl]amino] phenoxyphosphinyl]-methoxy]propyl]adenine (GS-7340) and other tenofovir phosphonoamidate prodrugs by human proteases. Mol. Pharmacol. 74, 92-100
95. Dutschman, G.E. et al. (2004) Novel 4′-substituted stavudine analog with improved anti-human immunodeficiency virus activity and decreased cytotoxicity. Antimicrob. Agents Chemother. 48, 1640-1646
96. Levin, J. et al. (2012) The HIV NRTI BMS-986001 does not degrade mitochondrial DNA in long term primary cultures of cells isolated from human kidney, muscle and subcutaneous fat. 19th International AIDS Conference Abstract # TUPE042
97. Paintsil, E. et al. (2009) A single-dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of OBP-601, a novel NRTI, in healthy subjects. 16th Conference on Retroviruses and Opportunistic Infections Abstract # 568
98. Cotte, L. et al. (2010) A phase Ib/2a dose escalation study of OBP-601 (4′ethynyl-d4T, festinavir) in treatment experienced, HIV-1-infected patients. 50th International Conference on Antimicrobial Agents and Chemotherapy Abstract # H933
99. Hwang, C. et al. (2012) Antiviral activity, exposure-response, and resistance analyses of monotherapy with the novel HIV nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 in antiretroviral treatment- experienced subjects. 13th International Workshop on Clinical Pharmacology of HIV Therapy Abstract # O-06
100. Maeda, K. et al. (2012) Delayed emergence of HIV-1 variants resistant to 4′-ethynyl-2-fluoro-2′-deoxyadenosine (EFdA): comparative sequential passage with tenofovir, emtricitabine and festinavir. AIDS 2012 Abstract # TUPE017
101. Sohl, C.D. et al. (2012) Balancing antiviral potency and host toxicity: identifying a nucleotide inhibitor with an optimal kinetic phenotype for HIV-1 reverse transcriptase. Mol. Pharmacol. 82, 125-133
102. Murphey-Corb, M. et al. (2012) Response of SIV to the novel nucleoside reverse transcriptase inhibitor 4′-ethynyl-2-fluoro-2′- deoxyadenosine (EFdA) in vitro and in vivo. Antimicrob. Agents Chemother. 56, 4707-4712
103. Sohl, C.D. et al. (2012) Mechanism of interaction of human mitochondrial DNA polymerase gamma with the novel nucleoside reverse transcriptase inhibitor 4′-ethynyl-2-fluoro-2′-deoxyadenosine indicates a low potential for host toxicity. Antimicrob. Agents Chemother. 56, 1630-1634